Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
Vandetanib has recently demonstrated clinically meaningful benefits in patients with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the potential for long-term vandetanib therapy in this setting, in addition to treatment for disease-related symptoms, effective management of related adverse events (AEs) is vital to ensure patient compliance and maximize clinical benefit with vandetanib therapy.
This expert meeting-based review aims to summarize published data on AEs associated with vandetanib therapy and to provide clinicians with specific practical guidance on education, monitoring, and management of toxicities induced in patients treated with vandetanib in advanced and metastatic MTC. The content of this review is based on the expert discussions from a multidisciplinary meeting held in October 2012.
Characteristics, frequency, and risk data are outlined for a number of dermatological, cardiovascular, gastrointestinal, and general AEs related to vandetanib treatment. Preventive strategies, practical treatment suggestions, and points for clinical consideration are provided.
Good patient and team communication is necessary for the prevention, early detection, and management of AEs of vandetanib. Physicians, nurses, and other healthcare providers play a critical role in providing AE management and patient support to optimize outcomes with vandetanib in MTC.
- Schlumberger, M, Bastholt, L, Dralle, H (2012) European Thyroid Association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J 1: pp. 5-14 CrossRef
- Roman, S, Lin, R, Sosa, JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107: pp. 2134-2142 CrossRef
- Carlomagno, F, Vitagliano, D, Guida, T (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62: pp. 7284-7290
- Wedge, SR, Ogilvie, DJ, Dukes, M (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: pp. 4645-4655
- AstraZeneca 2012. Caprelsa (vandetanib) tablets: US prescribing information. http://www.astrazeneca-us.com/pi/caprelsa.pdf (Accessed Sep 10, 2013).
- European Medicines Agency (EMA) 2012. Caprelsa (vandetanib): Summary of Product Characteristics, AstraZeneca. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002315/WC500123555.pdf (Accessed Sep 10, 2013).
- Wells, SA, Robinson, BG, Gagel, RF (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30: pp. 134-141 CrossRef
- Wells, SA, Gosnell, JE, Gagel, RF (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28: pp. 767-772 CrossRef
- Leboulleux, S, Bastholt, L, Krause, T (2012) Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13: pp. 897-905 CrossRef
- Brassard, M, Neraud, B, Trabado, S (2011) Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab 96: pp. 2741-2749 CrossRef
- Langmuir, PB, Yver, A (2012) Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther 91: pp. 71-80 CrossRef
- Zang, J, Wu, S, Tang, L (2012) Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS ONE 7: pp. e30353 CrossRef
- Thornton, K, Kim, G, Maher, VE (2012) Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 18: pp. 3722-3730 CrossRef
- Martin, P, Oliver, S, Kennedy, SJ (2012) Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther 34: pp. 221-237 CrossRef
- Robinson, BG, Paz-Ares, L, Krebs, A, Vasselli, J, Haddad, R (2010) Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95: pp. 2664-2671 CrossRef
- Rosen, AC, Wu, S, Damse, A, Sherman, E, Lacouture, ME (2012) Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 97: pp. 1125-1133 CrossRef
- Giacchero, D, Ramacciotti, C, Arnault, JP (2012) A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol 148: pp. 1418-1420 CrossRef
- Peuvrel, L, Bachmeyer, C, Reguiai, Z (2012) Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer 20: pp. 909-921 CrossRef
- Stahli, BE, Schwab, S (2011) Amiodarone-induced skin hyperpigmentation. QJM. 104: pp. 723-724
- Yoon, J, Oh, CW, Kim, CY (2011) Stevens–Johnson syndrome induced by vandetanib. Ann Dermatol 23: pp. S343-S345 CrossRef
- Joshi, SS, Ortiz, S, Witherspoon, JN (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116: pp. 3916-3923 CrossRef
- Boone, SL, Rademaker, A, Liu, D, Pfeiffer, C, Mauro, DJ, Lacouture, ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72: pp. 152-159 CrossRef
- Lacouture, ME, Anadkat, MJ, Bensadoun, RJ (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19: pp. 1079-1095 CrossRef
- Lynch, TJ, Kim, ES, Eaby, B, Garey, J, West, DP, Lacouture, ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12: pp. 610-621 CrossRef
- Lacouture, ME, Maitland, ML, Segaert, S (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18: pp. 509-522 CrossRef
- National Cancer Institute 2010. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 (Accessed Nov 22, 2012).
- Qi, WX, Shen, Z, Lin, F (2013) Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 75: pp. 919-930 CrossRef
- Perk, J, Backer, G, Gohlke, H (2012) European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med 19: pp. 403-488 CrossRef
- Isbister, GK, Page, CB (2013) Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol 76: pp. 48-57 CrossRef
- Chan, A, Isbister, GK, Kirkpatrick, CM, Dufful, SB (2007) Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 100: pp. 609-615 CrossRef
- Fazio, S, Palmieri, EA, Lombardi, G, Biondi, B (2004) Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 59: pp. 31-50 CrossRef
- Arizona Center for Education and Research on Therapeutics (AZERT). CredibleMeds(R) website. http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs (Accessed Sep 10, 2013).
- Hafermann, MJ, Namdar, R, Seibold, GE, Page, RL (2011) Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf 3: pp. 53-58
- Eisenberg, P, MacKintosh, FR, Ritch, P, Cornett, PA, Macciocchi, A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15: pp. 330-337 CrossRef
- European Medicines Agency (EMA) 2010. Aloxi (palonosetron) Summary of Product Characteristics, Helsinn Birex Pharmaceuticals Ltd. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000563/WC500024259.pdf (Accessed Sep 10, 2013).
- Gonullu, G, Demircan, S, Demirag, MK, Erdem, D, Yucel, I (2012) Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 20: pp. 1435-1439 CrossRef
- Yavas, C, Dogan, U, Yavas, G, Araz, M, Ata, OY (2012) Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer 20: pp. 2343-2347 CrossRef
- Rumore, MM (2012) Cardiovascular adverse effects of metoclopramide: review of literature. Int J Case Rep Images 3: pp. 1-10 CrossRef
- European Medicines Agency (EMA) 2008. Emend (aprepitant) Summary of Product Characteristics, Merck Sharp & Dohme. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000527/WC500026537.pdf (Accessed Sep 10, 2013).
- Food and Drug Administration (FDA) 2003. Aprepitant FDA Advisory Committee Background Package. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3928B1_01_Merck%20Backgrounder.pdf (Accessed Sep 10, 2013).
- Massicotte, MH, Borget, I, Broutin, S (2013) Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo controlled study. J Clin Endocrinol Metab 98: pp. 2401-2408 CrossRef
- Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Advances in Therapy
Volume 30, Issue 11 , pp 945-966
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Adverse effects
- Antineoplastic agents/adverse effects
- Medullary thyroid cancer
- Medullary thyroid carcinoma
- Patient safety
- Piperidines/therapeutic use
- Protein kinase inhibitors
- Thyroid neoplasms/drug therapy
- Industry Sectors
- Author Affiliations
- 1. Servicio de Oncología Médica, Hospital Ramón y Cajal, Carretera de Colmenar Viejo Km. 9.100, 28034, Madrid, Spain
- 11. Department of Nuclear Medicine, Central Hospital of Augsburg, Augsburg, Germany
- 2. Department of Nuclear Medicine, University Hospital of Wuerzburg, Wuerzburg, Germany
- 3. Department of Internal Medicine and Medical Specialities, University of Rome “Sapienza”, Rome, Italy
- 4. Thyroid Unit, Royal Marsden Hospital, Surrey, UK
- 5. Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
- 6. Department of Medical Oncology, Dermatology Unit and INSERM U981, Gustave Roussy Institute, University of Paris-Sud, Villejuif, France
- 7. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute, University of Paris-Sud, Villejuif, France
- 8. Department of Oncology, Clinical Research Unit, Odense University Hospital, Odense, Denmark
- 9. Cardiology Service, Hospital Ramón y Cajal, Madrid, Spain
- 10. Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain